Excitement among patients and researchers as custom-built jabs enter phase 3 trial
Doctors have begun trialling in hundreds of patients the world’s first personalised mRNA cancer vaccine for melanoma, as experts hailed its “gamechanging” potential to permanently cure cancer.
Melanoma affects about 132,000 people a year globally and is the biggest skin cancer killer. Currently, surgery is the main treatment although radiotherapy, medicines and chemotherapy are also sometimes used.
